In colorectal cancer cells, BETi treatment led to repression of MYC-driven expression of miR1271-5p, which in turn led to increased NOXA levels and inhibition of MCL-1, thereby enabling synergy with ABT-263. This evidence concerns the gene MCL1 and colorectal cancer.